Akums Reports Q4 FY25 with 12.4% Revenue Growth, Secures €200M Contract

Akums Drugs and Pharmaceuticals Ltd., India’s largest contract development and manufacturing organization (CDMO), has announced its consolidated financial results for the quarter and fiscal year ending March 31, 2025. The fourth quarter marked a significant rebound in performance, with a 12.4% year-on-year (YoY) growth in revenue. The company posted a 10.4% EBITDA margin. Akums secured an approx. €200 million contract for the manufacture and supply of pharmaceutical products to regulated European markets. The commercial supplies for this will begin in 2027. The company invested =272 crore in capital expenditure during FY25 and maintained a strong R&D focus, investing 130 crore. Akums reported flat year-on-year revenue due to muted industry volumes and price erosion in APIs. The company, however, continued to invest in long-term growth drivers to consolidate its leadership position in India’s pharmaceutical landscape and lay the foundation for global CDMO expansion.